How many drugs treat insomnia?

Drug Landscape tracks 10 marketed treatments for insomnia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/insomnia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

insomnia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

insomnia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating insomnia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Quviviq	DARIDOREXANT	Idorsia	Orexin Receptor Antagonist [EPC]	Orexin receptor type 1	2022-01-01
Dayvigo	LEMBOREXANT	Eisai	Orexin Receptor Antagonist [EPC]	Orexin receptor type 2	2019-01-01
Lunesta	ESZOPICLONE	Waylis	eszopiclone	Gamma-aminobutyric acid receptor subunit alpha-1	2004-01-01
Imovane	ZOPICLONE	Sunovion Pharms Inc	zopiclone	GABA A receptor alpha-5/beta-2/gamma-2	2004-01-01
Noctan	METHYPRYLON	Roche	methyprylon	GABA-A receptor alpha-1/beta-3/gamma-2	1982-01-01
Valmid	ETHINAMATE	Dista	ethinamate		1982-01-01
Prazene	PRAZEPAM	Parke Davis		GABA-A receptor alpha-1/beta-2/gamma-2	1982-01-01
Metabarbital	METHARBITAL	AbbVie	metharbital	GABA-A receptor; anion channel	1982-01-01
Glimid	GLUTETHIMIDE	Sandoz		GABA-A receptor alpha-1/beta-3/gamma-2	1976-01-01
Nembutal Sodium	PENTOBARBITAL	Oak Pharms	pentobarbital	GABA-A receptor alpha-1/beta-2/gamma-2	1973-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 18 drugs in insomnia
AbbVie · 2 drugs in insomnia
Brooke Army Medical Center · 1 drug in insomnia
Dista · 1 drug in insomnia
Eisai · 1 drug in insomnia
Idorsia · 1 drug in insomnia
Johnson & Johnson (McNeil Consumer Healthcare) · 1 drug in insomnia
Mallinckrodt · 1 drug in insomnia
National Institute on Drug Abuse (NIDA) · 1 drug in insomnia
Oak Pharms · 1 drug in insomnia
Parke Davis · 1 drug in insomnia
Professional Complementary Health Formulas · 1 drug in insomnia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in insomnia:

Cite this brief

Drug Landscape (2026). insomnia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/insomnia. Accessed 2026-06-10.

insomnia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing